Company / Operating Income
Editas Medicine, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$251.2M
FY2025
5-year range
-$251.2M / -$134.8M
FY2021-FY2025
Trend
-11.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 3 consecutive years, from -$135M in FY2022 to -$251M in FY2025.
Based on SEC 10-K filings.
-$251M in FY2025.
Declined from -$193M to -$251M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Editas Medicine, Inc.'s operating income has declined for 3 consecutive years.
- In FY2025, operating income decreased 11.2% year-over-year.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$251.2M | -11.2% |
| FY2024 | -$225.9M | -17.0% |
| FY2023 | -$193.1M | -43.2% |
| FY2022 | -$134.8M | +4.3% |
| FY2021 | -$140.9M | -23.9% |
| FY2020 | -$113.7M | +5.2% |
| FY2019 | -$119.9M | -23.4% |
| FY2018 | -$97.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026